Supriya Lifescience quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	190	145	+30.8%
EBITDA	47.5	51.7	−8.2%
EBITDA margin	25.0%	35.6%	−10.6 pts
Profit before tax	40.8	47.4	−14.0%
Net profit	24.0	34.8	−30.9%
EPS	₹2.99	₹4.32	−30.8%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023

Expenses
	190	277	206	200	145	184	186	166	161	158	140	140
	2.6	3.5	2.6	2.7	2.7	3.0	2.1	2.5	2.2	2.2	3.1	2.5
	192	280	209	203	148	187	188	169	163	160	143	143
	109	83.4	77.3	60.7	43.8	102	13.6	61.6	55.7	48.4	44.8	50.7
	−53.0	22.0	−16.1	−5.0	−12.0	−46.7	48.2	−15.6	−7.1	9.9	9.8	10.9
	28.5	24.8	24.7	24.5	22.7	21.0	19.8	19.7	20.1	17.1	17.6	17.5
	0.4	0.5	0.5	0.4	0.5	0.4	0.5	0.4	0.3	0.6	0.5	0.5
	8.9	8.5	6.8	6.6	6.5	6.1	5.0	4.7	4.7	3.9	4.0	4.0
	57.4	48.8	48.5	47.0	38.9	40.7	38.1	35.7	29.4	27.3	26.4	29.2
	152	188	142	134	100	123	125	107	103	107	103	113
	47.5	97.6	72.1	72.6	51.7	67.6	66.0	64.7	62.5	55.5	41.5	31.8
	38.5	89.1	65.3	66.0	45.3	61.5	61.0	60.0	57.9	51.6	37.5	27.8
Profit
	40.8	92.1	67.4	68.3	47.4	64.1	62.6	62.1	59.8	53.2	40.1	29.8
	0.0	0.0	−0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	40.8	92.1	66.9	68.3	47.4	64.1	62.6	62.1	59.8	53.2	40.1	29.8
	8.5	20.4	15.3	15.2	10.5	12.8	13.8	15.4	14.7	8.9	9.7	8.5
	8.2	−2.5	1.9	2.7	2.1	0.9	2.0	0.5	0.5	7.3	0.7	−2.6
	16.7	17.9	17.2	17.9	12.6	13.7	15.8	15.9	15.1	16.2	10.3	5.9
	24.0	74.2	49.7	50.4	34.8	50.4	46.8	46.1	44.6	36.9	29.8	23.9
	24.0	74.2	49.7	50.4	34.8	50.4	46.8	46.1	44.6	36.9	29.8	23.9
	0.6	0.0	0.0	0.0	−0.2	0.1	0.1	−0.2	−0.1	0.1	0.3	−0.1
	24.7	74.3	49.7	50.5	34.6	50.5	46.8	45.9	44.6	37.0	30.1	23.7
Per share
	₹2.99	₹9.22	₹6.17	₹6.27	₹4.32	₹6.29	₹5.82	₹5.71	₹5.54	₹4.59	₹3.70	₹2.97
	₹2.99	₹9.22	₹6.17	₹6.27	₹4.32	₹6.29	₹5.82	₹5.71	₹5.54	₹4.59	₹3.70	₹2.97
Other comprehensive income — detail
	0.6	0.0	0.0	0.0	−0.2	0.1	—	—	—	—	—	—
	0.9	0.1	0.1	0.0	−0.3	0.1	0.1	−0.3	−0.1	0.0	0.4	−0.2
	0.2	0.0	0.0	0.0	−0.1	0.0	—	—	—	—	—	—
	—	—	—	—	—	—	0.0	−0.1	−0.0	−0.0	0.1	−0.0
Per share — as-filed variants
	₹2.99	₹9.22	₹6.17	₹6.27	₹4.32	₹6.29	₹5.82	₹5.71	₹5.54	₹4.59	₹3.70	₹2.97
	₹2.99	₹9.22	₹6.17	₹6.27	₹4.32	₹6.29	₹5.82	₹5.71	₹5.54	₹4.59	₹3.70	₹2.97
Regulatory disclosures — filed alongside, not part of the P&L
	—	21.1	—	16.3	—	18.9	—	—	—	—	—	—
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	133	171	145	144	113	129	124	120	112	99.9	85.5	78.5
	70.3%	61.9%	70.4%	72.1%	78.1%	70.2%	66.7%	72.3%	69.7%	63.2%	61.0%	56.0%
Adjusted (ex-exceptional items) — derived
	40.8	92.1	67.4	68.3	47.4	64.1	62.6	62.1	59.8	53.2	40.1	29.8
	0.0	0.0	−0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	24.0	74.2	50.0	50.4	34.8	50.4	46.8	46.1	44.6	36.9	29.8	23.9
	₹2.99	₹9.22	₹6.21	₹6.27	₹4.32	₹6.29	₹5.82	₹5.71	₹5.54	₹4.59	₹3.70	₹2.97

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SUPRIYA₹811.50

Supriya Lifescience Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersSTAR SPARC THYROCARE SHILPAMED VIYASH RUBICON YATHARTH PARKHOSPS

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	140.1	140.1	158.2	160.6	166.1	185.6	184.1	145.1	199.8	206.4	276.5	189.7
Other Income	2.5	3.1	2.2	2.2	2.5	2.1	3.0	2.7	2.7	2.6	3.5	2.6
Total Income	142.6	143.1	160.4	162.9	168.6	187.7	187.1	147.7	202.6	209.1	280.0	192.4
Expenses
+ Cost of Materials Consumed	50.7	44.8	48.4	55.7	61.6	13.6	101.5	43.8	60.7	77.3	83.4	109.4
+ Changes in Inventories	10.9	9.8	9.9	-7.1	-15.6	48.2	-46.7	-12.0	-5.0	-16.1	22.0	-53.0
+ Employee Benefit Expense	17.5	17.6	17.1	20.1	19.7	19.8	21.0	22.7	24.5	24.7	24.8	28.5
+ Finance Costs	0.5	0.5	0.6	0.3	0.4	0.5	0.4	0.5	0.4	0.5	0.5	0.4
+ Depreciation & Amortisation	4.0	4.0	3.9	4.7	4.7	5.0	6.1	6.5	6.6	6.8	8.5	8.9
+ Other Expenses	29.2	26.4	27.3	29.4	35.7	38.1	40.7	38.9	47.0	48.5	48.8	57.4
Total Expenses	112.8	103.0	107.2	103.1	106.6	125.2	123.0	100.3	134.2	141.7	187.9	151.6
EBITDA	31.8	41.5	55.5	62.5	64.7	66.0	67.6	51.7	72.6	72.1	97.6	47.5
EBIT	27.8	37.5	51.6	57.9	60.0	61.0	61.5	45.3	66.0	65.3	89.1	38.5
Profit
PBT before Exceptional Items	29.8	40.1	53.2	59.8	62.1	62.6	64.1	47.4	68.3	67.4	92.1	40.8
+ Exceptional Items	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.5	0.0	0.0
Pretax Income	29.8	40.1	53.2	59.8	62.1	62.6	64.1	47.4	68.3	66.9	92.1	40.8
+ Current Tax	8.5	9.7	8.9	14.7	15.4	13.8	12.8	10.5	15.2	15.3	20.4	8.5
+ Deferred Tax	-2.6	0.7	7.3	0.5	0.5	2.0	0.9	2.1	2.7	1.9	-2.5	8.2
Tax Expense	5.9	10.3	16.2	15.1	15.9	15.8	13.7	12.6	17.9	17.2	17.9	16.7
Net Income	23.9	29.8	36.9	44.6	46.1	46.8	50.4	34.8	50.4	49.7	74.2	24.0
+ Net Income — Continuing Ops	23.9	29.8	36.9	44.6	46.1	46.8	50.4	34.8	50.4	49.7	74.2	24.0
+ Other Comprehensive Income	-0.1	0.3	0.1	-0.1	-0.2	0.1	0.1	-0.2	0.0	0.0	0.0	0.6
Total Comprehensive Income	23.7	30.1	37.0	44.6	45.9	46.8	50.5	34.6	50.5	49.7	74.3	24.7
Per Share
Basic EPS	2.97	3.70	4.59	5.54	5.71	5.82	6.29	4.32	6.27	6.17	9.22	2.99
Diluted EPS	2.97	3.70	4.59	5.54	5.71	5.82	6.29	4.32	6.27	6.17	9.22	2.99
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	0.1	-0.2	0.0	0.0	0.0	0.6
+ Items NOT to be Reclassified to P&L	-0.2	0.4	0.0	-0.1	-0.3	0.1	0.1	-0.3	0.0	0.1	0.1	0.9
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	0.0	-0.1	0.0	0.0	0.0	0.2
+ Tax on Items NOT to be Reclassified — alt tag	-0.0	0.1	-0.0	-0.0	-0.1	0.0	—	—	—	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	2.97	3.70	4.59	5.54	5.71	5.82	6.29	4.32	6.27	6.17	9.22	2.99
Diluted EPS — Continuing Operations	2.97	3.70	4.59	5.54	5.71	5.82	6.29	4.32	6.27	6.17	9.22	2.99
Regulatory Disclosures — filed alongside, not part of the P&L
Related-party Transactions — During the Period	—	—	—	—	—	—	18.9	—	16.3	—	21.1	—
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	78.5	85.5	99.9	112.0	120.1	123.9	129.3	113.3	144.1	145.2	171.2	133.4
Gross Margin %	56.00	61.01	63.17	69.75	72.32	66.72	70.22	78.10	72.11	70.35	61.91	70.28
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	29.8	40.1	53.2	59.8	62.1	62.6	64.1	47.4	68.3	67.4	92.1	40.8
− Exceptional Items (reconciliation)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.5	0.0	0.0
Net Income Adj (tax-effected)	23.9	29.8	36.9	44.6	46.1	46.8	50.4	34.8	50.4	50.0	74.2	24.0
EPS Adj	2.97	3.70	4.59	5.54	5.71	5.82	6.29	4.32	6.27	6.21	9.22	2.99
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Paid Up Equity Capital	16.1	16.1	16.1	16.1	16.1	16.1	16.1	16.1	16.1	16.1	16.1	16.1

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Supriya Lifescience Q2 FY27 results date

Supriya Lifescience (NSE: SUPRIYA) will announce its Q2 FY27 results (July–September 2026) on Friday, 6 November 2026, according to the board-meeting notice it filed on 30 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit was ₹24 crore, down 30.9% from ₹34.8 crore in Q1 FY26 and down 67.6% from ₹74.2 crore in Q4 FY26. Revenue from operations was ₹190 crore, up 30.8% year on year and down 31.4% from the previous quarter.

Board-meeting notice filed: 30 October 2026
Q2 FY26 results (a year earlier): 12 November 2025
Q1 FY27 results (the latest): 13 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 6 November 2026Friday · notice filed 30 Oct
Q1 FY27 net profit: ₹24 Cr−30.9% vs Q1 FY26−67.6% vs Q4 FY26
Q1 FY27 revenue: ₹190 Cr+30.8% vs Q1 FY26−31.4% vs Q4 FY26
Q1 FY27 operating margin: 20.3%−10.9 pts vs Q1 FY26−11.9 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹50.4 CrRevenue ₹200 Cr
Q1 FY27 EPS (basic): ₹2.99

Questions

When will Supriya Lifescience announce its Q2 FY27 results?

On 6 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 30 October 2026). Last year it reported Q2 FY26 on 12 November 2025.

What will Supriya Lifescience's Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit was ₹50.4 crore and revenue from operations ₹200 crore. The latest quarter, Q1 FY27, had a net profit of ₹24 crore and revenue of ₹190 crore.

What were Supriya Lifescience's Q1 FY27 results?

Consolidated net profit was ₹24 crore, down 30.9% from ₹34.8 crore in Q1 FY26 and down 67.6% from ₹74.2 crore in Q4 FY26. Revenue from operations was ₹190 crore, up 30.8% year on year and down 31.4% from the previous quarter.

How has Supriya Lifescience's profit changed over the last four quarters?

Net profit by quarter: ₹50.4 crore in Q2 FY26, ₹49.7 crore in Q3 FY26, ₹74.2 crore in Q4 FY26 and ₹24 crore in Q1 FY27. That is ₹198 crore over the four quarters, up 11.4% from ₹178 crore in the four quarters before. Revenue from operations: ₹200 crore, ₹206 crore, ₹277 crore and ₹190 crore.

Where do these Supriya Lifescience figures come from?

From Supriya Lifescience's own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.